INT200218

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 2006
Last Reported 2006
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 23
Disease Relevance 48.58
Pain Relevance 4.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (SDHD) mitochondrion (SDHD) small molecule metabolic process (SDHD)
Anatomy Link Frequency
plasma 3
neck 3
head 3
urine 2
body 1
SDHD (Homo sapiens)
Pain Link Frequency Relevance Heat
Catecholamine 690 99.78 Very High Very High Very High
imagery 276 99.24 Very High Very High Very High
headache 69 99.00 Very High Very High Very High
Dopamine 69 97.36 Very High Very High Very High
Somatostatin 23 95.52 Very High Very High Very High
medulla 46 95.04 Very High Very High Very High
Neuropeptide 46 91.20 High High
Catechol-O-methyltransferase 23 85.76 High High
noradrenaline 92 79.76 Quite High
Clonidine 23 45.76 Quite Low
Disease Link Frequency Relevance Heat
Pheochromocytoma 1150 100.00 Very High Very High Very High
Paraganglioma 1104 100.00 Very High Very High Very High
Disease 460 100.00 Very High Very High Very High
Pancreatic Cancer 23 100.00 Very High Very High Very High
Brain Tumor 23 100.00 Very High Very High Very High
Hypercalcemia 23 99.86 Very High Very High Very High
Cancer 1219 99.76 Very High Very High Very High
Thyroid Neoplasm 23 99.44 Very High Very High Very High
Malignant Neoplastic Disease 253 99.40 Very High Very High Very High
Headache 69 99.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The diagnosis of PH or secreting PGL is excluded in these cases by the normalization of metanephrines ten days after the onset of the event [14].
Localization (secreting) of PGL associated with paraganglioma and pheochromocytoma
1) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.02 Pain Relevance 0.25
Where these imaging methods give negative (mostly in non-secreting PGL) or discordant results, the investigation should be completed by scintigraphy with nonspecific ligands such as somatostatin receptor scintigraphy or [18F]fluorodeoxyglucose PET, fluoro-DOPA or fluoro-dopamine PET.
Localization (secreting) of PGL associated with dopamine, somatostatin, paraganglioma and imagery
2) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.72 Pain Relevance 0.56
In decreasing order of frequency, secreting PGL may develop in the Zuckerkandl body, a vestigial chromaffin ganglion located at the root of the upper mesenteric artery, in the sympathetic plexus of the urinary bladder, the kidneys and the heart, or in sympathetic ganglia in the mediastinum, the head or the neck.
Localization (secreting) of PGL in body associated with ganglion cysts and paraganglioma
3) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.65 Pain Relevance 0.22
Positive diagnosis of PH and secreting PGL is chiefly based on the quantification of plasma or urinary metanephrines, as this test is more sensitive than both the quantification of urinary vanillyl-mandelate acid or plasma catecholamines [2,3,14-16], and plasma neuropeptide Y or chromogranin A determinations [17,18].
Localization (secreting) of PGL in plasma associated with catecholamine, neuropeptide, paraganglioma and pheochromocytoma
4) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.50 Pain Relevance 0.59
Patients with hereditary PGL or with VHL disease may harbor both secreting and non-secreting PGL, making the differential diagnosis of the individual tumor difficult.


Localization (secreting) of PGL associated with cancer, paraganglioma and disease
5) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.51 Pain Relevance 0.14
Ten percent of catecholamine-producing tumors arise from extraadrenal chromaffin tissue and are called extraadrenal PH or secreting paragangliomas (PGL).
Localization (secreting) of PGL associated with cancer, catecholamine, paraganglioma and pheochromocytoma
6) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.63 Pain Relevance 0.19
Most head and neck PGL are non-secreting.
Localization (secreting) of PGL in neck associated with paraganglioma
7) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.83 Pain Relevance 0.33
Non-secreting PGL can be differentiated from secreting PGL by normal concentrations of catecholamines and metanephrines in the plasma and urine.
Localization (secreting) of PGL in urine associated with catecholamine and paraganglioma
8) Confidence 0.69 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.36 Pain Relevance 0.21
Genetic testing is indicated for all patients with PGL and/or PH, whatever the location of the tumor and the age of the subjects, but such testing may also be indicated by clinical and familial features (Figure 1).
Localization (location) of PGL associated with cancer, paraganglioma and pheochromocytoma
9) Confidence 0.64 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.51 Pain Relevance 0.03
Targeted genetic testing should be proposed to patients with phenotypic clues and/or familial history for MEN-2 (medullary thyroid cancer, hyperparathyroidism), VHL disease (hemangioblastoma, renal or pancreatic tumors), or hereditary PGL (head and neck PGL, familial history in the paternal branch).
Localization (disease) of PGL in neck associated with thyroid neoplasm, pancreatic cancer, paraganglioma, hypercalcemia, disease and brain tumor
10) Confidence 0.64 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.52 Pain Relevance 0.03
Targeted genetic testing should be proposed to patients with phenotypic clues and/or familial history for MEN-2 (medullary thyroid cancer, hyperparathyroidism), VHL disease (hemangioblastoma, renal or pancreatic tumors), or hereditary PGL (head and neck PGL, familial history in the paternal branch).
Localization (disease) of PGL in neck associated with thyroid neoplasm, pancreatic cancer, paraganglioma, hypercalcemia, disease and brain tumor
11) Confidence 0.64 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.51 Pain Relevance 0.03
Non-secreting PGL can be differentiated from secreting PGL by normal concentrations of catecholamines and metanephrines in the plasma and urine.
Localization (secreting) of PGL in urine associated with catecholamine and paraganglioma
12) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.36 Pain Relevance 0.21
In carriers of SDHB mutations, the resulting tumor is usually a secreting or non-secreting PGL, which may be malignant [4,24,26].
Localization (secreting) of PGL associated with malignant neoplastic disease, cancer and paraganglioma
13) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.74 Pain Relevance 0
Patients with hereditary PGL or with VHL disease may harbor both secreting and non-secreting PGL, making the differential diagnosis of the individual tumor difficult.


Localization (secreting) of PGL associated with cancer, paraganglioma and disease
14) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.49 Pain Relevance 0.14
The increased production of catecholamines by PH and secreting PGL causes symptoms (mainly headaches, palpitations and excess sweating) and signs (mainly hypertension, weight loss and diabetes) that reflect the effects of catecholamines on ?
Localization (secreting) of PGL associated with heart rate under development, diabetes mellitus, catecholamine, pheochromocytoma, weight loss, hypertension, headache and paraganglioma
15) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.14 Pain Relevance 0.41
The etiology of tumorigenesis in PH and secreting PGL is unknown, although valuable information has recently been provided by work on the genomics of familial diseases including these tumors.
Localization (secreting) of PGL associated with cancer, paraganglioma, disease and pheochromocytoma
16) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.89 Pain Relevance 0.07
In carriers of SDHB mutations, the resulting tumor is usually a secreting or non-secreting PGL, which may be malignant [4,24,26].
Localization (secreting) of PGL associated with malignant neoplastic disease, cancer and paraganglioma
17) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.73 Pain Relevance 0
PH and secreting PGL are defined by the synthesis and/or secretion of catecholamines: dopamine, norepinephrine and/or epinephrine.
Localization (secreting) of PGL associated with dopamine, catecholamine, paraganglioma and pheochromocytoma
18) Confidence 0.60 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.90 Pain Relevance 0.37
Non-secreting PGL can be differentiated from secreting PGL by normal concentrations of catecholamines and metanephrines in the plasma and urine.
Localization (secreting) of PGL in plasma associated with catecholamine and paraganglioma
19) Confidence 0.23 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 2.36 Pain Relevance 0.21
Most head and neck PGL are non-secreting.
Localization (secreting) of PGL in head associated with paraganglioma
20) Confidence 0.23 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1702343 Disease Relevance 1.83 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox